报告题目：Multidimensional immunoengineering approaches to enhanced cancer immunotherapy
报告人：唐力 副教授瑞士洛桑联邦理工学院
报告时间：2024年3月12日15:00
报告地点：生科院二楼221会议室
邀请人：李子福 教授
专家简介：
唐力教授2007年毕业于北京大学化学学院并获得理学学士学位，2012年获得美国伊利诺伊大学厄本那香槟分校（UIUC）材料科学和工程学博士学位, 师从程建军教授。2013至2016年，作为CRI Irvington Postdoctoral Fellow在美国麻省理工学院（MIT）从事博士后研究，师从免疫工程领域先驱Darrell J. Irvine教授。2016年8月被瑞士洛桑联邦理工学院（EPFL）生物工程系和材料科学与工程系聘为助理教授（Tenure Track），博士生导师，并独立建立免疫工程及生物材料实验室。于2022年晋升为副教授（终身教职）。
唐力教授课题组的研究重点是开发用于增强癌症免疫疗法的多维免疫工程方法，从生物、化学、代谢和机械物理多维度出发，探索安全有效且有持续性的癌症免疫治疗新方法。至今，作为第一作者、通讯作者在Nature Biotechnology（2篇）、Nature Immunology、Nature Nanotechnology、Nature Biomedical Engineering、Science Advances、 Proc. Natl. Acad. Sci.等国际顶级学术期刊上发表论文50余篇。唐力教授同时致力于实验室成果的转化，是深圳莱芒生物联合创始人。作为发明人获得12项国际专利授权，其中5项科研成果已转化并进入或启动临床试验。其实验室研发的代谢增强型CAR-T细胞疗法已经在临床上连续治愈十余例难治或复发性B细胞淋巴瘤或白血病患者。唐力教授同时还担任Immuno-Oncology Technology副主编，和多个期刊编委。
唐力教授曾获得欧盟研究理事会授予的ERC Starting Grant Award、癌症研究所CRI的CLIP奖、安娜-富勒奖，并入选麻省理工科技评论中国区“35岁以下科技创新35人”名单, Nano Research、Materials Horizon、Biomaterials Science的新兴研究员等奖项。被Cell, Nature Biotechnology, Nature Nanotechnology, Nature Biomedical Engineering, Nature Cancer, Nature Communications, Science Translational Medicine, Science Advances等60余个国际权威学术期刊邀请担任科研论文审稿人。还受邀担任过中国（如新基石）及欧洲（ERC）、瑞士、比利时、荷兰、法国、丹麦、以色列等科研基金的评审专家。
报告摘要：
Our immune system interacts with many diseases in a multidimensional manner involving substantial biological, chemical, and physical exchanges. Manipulating the disease-immunity interactions may afford novel immunotherapies to better treat diseases such as cancer. My lab aims to develop novel strategies to engineer the multidimensional immunity-disease interactions (or termed ‘immunoengineering’) to create safe and effective therapies against cancer. We leverage the power of metabolic and cellular bioengineering, synthetic chemistry and material engineering, and mechanical engineering to achieve controllable modulation of immune responses. In this talk, I will first discuss a new type of immune checkpoint with mechanical basis that is distinct from most known immune checkpoints of biochemical traits. We further developed a mechanical intervention to overcome the mechanical immune checkpoint for enhanced cancer immunotherapy. Next, I will share our recent discovery of IL-10 as a metabolic reprogramming agent that reinvigorates the terminally exhausted CD8+ tumor infiltrating lymphocytes. This strategy has been extended to develop metabolically armored CAR-T cells with IL-10 secretion to counter exhaustion-associated dysfunction in the tumor microenvironment for enhanced anticancer immunity. This new CAR-T cell therapy, i.e. IL-10-secreting CAR-T, has shown promise in several on-going IIT clinical trials (ClinicalTrials.gov ID: NCT05715606, NCT05747157, NCT06120166) in the treatment of refractory/relapsed CD19+ B cell leukemia and lymphoma.
欢迎广大师生积极参加！
